Introduction
============

Colorectal Cancer (CRC) is one of the most frequent cancers in the western world. It represents the third most common cause of cancer-related deaths in the USA and in Europe it was estimated that more than 440,000 people were diagnosed with CRC in 2012.[@B1],[@B2] Within the last two decades, the standard treatment of locally advanced Union International contre le Cancer (UICC) II/III rectal cancer consists of a preoperative 5-FU-based chemoradiotherapy (CRT) followed by total mesorectal excision (TME)[@B3]-[@B5] because it was significantly associated with improved locoregional control, rate of sphincter preservation and long-term survival with favourable acute and late toxicity profiles compared to postoperative CRT.[@B6]-[@B9]

Although advances in chemotherapy and the development of specific antibody therapies, surgery as well as radiation therapy have been made, long-term outcome and disease-free survival rates still have not improved.[@B10] The long-term prognosis is limited due to the fact that 30% to 40% of patients with CRC still develop distant metastases in the further course of disease.[@B3],[@B11],[@B12] Furthermore, each treatment modality has its own side effects, which can be severe and an even intensified therapy can compromise patients\' quality of life. Thus, an individualised risk-adapted treatment for each individual patient would be desirable. However, until today, no reliable biomarker has been established in consideration of response prediction to preoperative CRT and individual prognosis in the clinical routine.[@B13]-[@B16]

Clinical trials (e.g. CAO/ARO/AIO-04 trial; study number: NCT00349076) have been testing intensified preoperative CRT protocols in order to improve local treatment efficacy and postoperative chemotherapy (CTx). The aim is to prolong disease-free survival (DFS) to ultimately enable a better long-term outcome.[@B17]-[@B22] However until today, we cannot clearly predict which patient benefits from an intensified therapy. This is why the implementation of biomarkers in clinical settings is needed.

The SRC gene is a proto-oncogene encoding for the SRC tyrosine kinase.[@B23] Though its role in cancer is still not fully understood, an overexpression of the SRC protein as well as an increase in its specific activity has been observed in numerous cancer types.[@B24],[@B25] Especially gastrointestinal cancer types like colorectal cancer show increased SRC activity.[@B26] SRC plays a central role in the regulation of cell differentiation, adhesion, migration, invasion, proliferation, angiogenesis and immune function.[@B24],[@B27]-[@B28]

Therefore the role of SRC expression considering its predictive and prognostic potential in locally advanced rectal cancer tissue was analysed.

For this, the expression of SRC was assessed in pretherapeutic biopsies and residual tumour tissue of locally advanced stage (cUICC II/III) rectal cancer after CRT and TME surgery in 186 patients using immunohistochemical staining (see figure [1](#F1){ref-type="fig"}).

Materials and Methods
=====================

Patient cohort
--------------

One hundred and eighty-six consecutive patients (median: 63.7 years; 130 men (69.9%), 56 women (30.1%)) with rectal adenocarcinomas clinically diagnosed as UICC II and III were included in this monocentric retrospective analysis. All patients were treated within phase-II/III trials of the German Rectal Cancer Study Group (e.g. CAO/ARO/AIO-94, CAO/ARO/AIO-04).[@B3],[@B29]-[@B30] Among these patients, 103 (55.4%) were treated with preoperative CRT with 5-FU or with 5-FU + oxaliplatin (n=56; 30.1%). Another 27 patients (14.5%) received primary surgery followed by postoperative CRT or in case of a tumor localization in the upper third of the rectum (12 to 16cm) by postoperative CTx with 5-FU + oxaliplatin (GAST-05 trial). The eligibility criteria included histologically confirmed adenocarcinoma and localization within 16 cm above the anocutaneous verge measured by rigid rectoscopy.[@B31] Staging procedures included endorectal ultrasonography, contrast-enhanced computer tomography (CT) scans of the abdomen and pelvis and/or magnetic resonance imaging (MRI) of the pelvis in order to confirm locally advanced but resectable rectal cancer. Every patient was treated at the Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen (UMG), Germany, between May 1998 and February 2010. Clinicopathological parameters of all patients and histopathological characteristics are summarized in table [1](#T1){ref-type="table"}. The informed consent for additional translational research projects and the approval from the ethics committee of the UMG were obtained from all patients before enrollment into this study (ethics committee approval number 9/8/08).

CRT and Surgery - Multimodal Treatment
--------------------------------------

Irradiation for patients receiving preoperative CRT was delivered with a total dose of 50.4Gy[@B32] in 28 fractions of 1.8Gy as 3-dimensional conformal irradiation, by intensity-modulated radiotherapy or volumetric intensity-modulated arc therapy with 6 or 20 megavolt (MV) photons.[@B33] In 103 patients receiving 5-FU based CRT, 5-FU was applied as 120-hour infusion of 1000mg/m^2^/d during weeks 1 and 5. The same regimen was performed postoperatively to the patients getting postoperative CRT. In 56 patients being randomized to an intensified chemotherapy regimen, preoperative CRT was applied as combination of 5-FU (250mg/m^2^/d) on days 1 to 14 and 22 to 35 and oxaliplatin (50mg/m^2^/d) on days 1, 8, 22 and 29. Six weeks after completion of preoperative CRT, quality-controlled TME surgery was performed.

After four to six weeks after surgery, multimodal treatment was completed with 4 cycles of 5-FU (500mg/m^2^/d) bolus infusions (days 1 to 5) or with 4 cycles of 5-FU (2400mg/m^2^) continuous infusion combined with oxaliplatin (100mg/m^2^) and folinic acid (400mg/m^2^) infusion.

Tumor Regression Grading and Histopathologic Staging
----------------------------------------------------

The semiquantitative 5-point Dworak tumor regression grading (TRG) system, classifying residual tumor tissue, was used as an early surrogate parameter in order to estimate therapeutic response to preoperative CRT.[@B6],[@B34] Histopathologically confirmed pathological Complete Response (pCR) was defined as absence of any vital tumor cells in the area of the primary cancer and of all detected lymph nodes (ypT0N0).

Histopathological staging included current TNM stage classification.[@B35], [@B36] Nodal staging was evaluated histopathologically examining all detected lymph nodes and the determination of the lymph node ratio in all cases.

Study Cohorts for SRC Analysis
------------------------------

Tumor tissue was collected at two different time points: first during diagnostic biopsy procedure and second at the time of TME surgery. Pretreatment biopsies fulfilling the minimal quality criteria (≥ 50 carcinoma cells) were available from 152 patients. Resection specimens with ≥ 100 carcinoma cells were suitable for evaluation and were available from 163 samples. As a result 129 matched pairs of biopsies and corresponding resection specimens were identified.

Determination of SRC Status
---------------------------

The SRC status was assessed using paraffin-embedded tissue samples, which were cut into slices of 2μm. Using the monoclonal rabbit antibody *anti-SRC (36D10) Rabbit mAb*(Cell Signal, Boston, MA, 1:2000 diluted), a standardized immunohistochemical staining technique was performed on a Ventana Bench-Mark XT immunostainer (Ventana, Tucson, AZ). The heat epitope retrieval was performed for 60 minutes at 100°C (pH=9). The anti-SRC antibody was incubated at 37°C for 30 minutes. The enzymatic reactivity was visualized by means of horseradish peroxidase using the ultraView Universal DAB Detection Kit (Ventana Medical Systems).

As SRC is localized in the cytosol as well as in the membrane, both staining localizations were analyzed. For cytoplasmic staining, four different staining intensity grades were defined: 0 (no staining), 1 (weak staining), 2 (strong staining), 3 (very strong staining). For membrane staining, another four grades were defined: 3 (differentiation of membrane staining at low magnification (5x) was possible), 2 (differentiation of membrane staining at medium magnification (20x) was possible), 1 (differentiation of membrane staining at high magnification (40x) was possible), 0 (even at highest magnification (40x) no differentiation of membrane staining was possible).

Follow-up
---------

Follow-up examinations of all patients were performed at 3-month intervals within the first 2 years and at 6-month intervals after 2 years for a period of 10 years[@B31], according to the study protocols or national guidelines.[@B30],[@B31] DFS was defined as the period between surgical resection of the primary and any evidence of cancer recurrence. CSS was defined as the interval between the surgical resection of the primary rectal cancer and cancer-related death.

Statistical Analysis
--------------------

SRC expression was correlated with clinicopathological parameters (uT, uN, TRG, (y)pT, (y)pN, M status, (y)pUICC) and DFS, CSS and overall survival (OS). The workflow for the preprocessing and the analysis of the data was implemented using KNIME 2.7.0.[@B37] KNIME nodes were mostly used for the preprocessing of the data, while we used the R-plugin nodes in KNIME to perform the final statistical tests with R version 3.0.2. The global significance level was set to α=5%. For comparisons of continuous data we used the Pearson\'s correlation coefficient (r). If the data was skewed we used the non-parametric, rank based correlation coefficient (tau) according to Kendall. For comparisons of two continuous data distributions we used the Wilcoxon rank sum test, paired where applicable. In case of three or more different distribution samples we used the Kruskal-Wallis rank sum test for the comparison. The impact of SRC on DFS, CSS was determined using Kaplan-Meier analysis and assessed for statistical significance using the log rank test (as Cox proportional hazard model with binary input) and where applicable for the continuous data values using a Cox proportional hazard model. The survival analysis was performed using the R package survival.

In order to quantify immunohistochemical staining the H-Score was implemented, ranging from 0 (weakest staining) until 300 (strongest staining) by multiplicating intensity of staining with the percentage of stained tissue.[@B38]

Results
=======

Patient Characteristics and Recurrence
--------------------------------------

With respect to the primary tumor localization of rectal adenocarcinoma at the time of pretherapeutic staging (table [1](#T1){ref-type="table"}), 78 (41.9%) tumors were localized in the lower third (0-6cm), 94 (50.5%) tumors were localized in the middle third (\>6-12cm), and 14 (7.5%) tumors were localized in the upper third (\>12-16cm) of the rectum. The surgical procedures performed were 126 (67.7%) low anterior resections, 56 (30.1%) abdominoperineal resections and 4 discontinuous resections (Hartmann´s procedure) (2.2%), all including TME. Considering the efficacy of preoperative CRT in this study, the pretherapeutic cUICC staging and postoperative ypUICC tumor staging results are summarized in table [1](#T1){ref-type="table"}. The median follow-up was 71.6 months. The local and/or distant cancer recurrences were observed in 51 (32.0%) patients after preoperative CRT and in 10 (37.0%) patients after primary surgery followed by postoperative C(R)T (table [1](#T1){ref-type="table"}). In 56 patients having distant metastases, the predominant localizations of cancer relapse were pulmonal in 18 (32.1%) cases and hepatic metastases in 16 patients (28.6%)

Pretherapeutic SRC expression and prognosis
-------------------------------------------

SRC expression was overall higher in the resection specimens compared to the expression in pretherapeutic biopsies (mean H-Score in biopsies: 229; mean H-score in resection specimen: 254). A high pretherapeutic SRC expression level was associated with a negative postoperative nodal status (p=0.005; see figure [3](#F3){ref-type="fig"}A). Furthermore, there was a non-significant trend for prolonged CSS (p=0.059) and fewer local relapses (p=0.06) during long-term follow-up. In addition, even in patients with a positive nodal status, increased SRC expression was associated with a longer DFS (p=0.026). Besides, these patients also developed fewer distant metastases (p=0.04). Patients who underwent preoperative CRT with 5-FU + oxaliplatin with a high SRC expression in pretherapeutic biopsies showed more often a negative nodal status compared to those patients who were treated with RT and 5-FU alone (see figure [3](#F3){ref-type="fig"}B). The current study could not reveal a significant association between the pretherapeutic SRC expression level and the CRT-induced histopathological TRG.

SRC expression in resection specimens
-------------------------------------

The expression of SRC in resection specimens correlated significantly with the development of fewer distant metastases (p=0.048; see figure [4](#F4){ref-type="fig"}). Moreover we observed the trend that high SRC expression in patients who received preoperative CRT was associated with a negative nodal status (p=0.06). There was no statistically significant correlation between SRC expression in residual tumor tissue and DFS or local relapses during long-term follow up. In patients who received a preoperative CRT with 5-FU + oxaliplatin there was a trend for a longer CSS (p=0.06) for patients with high SRC expression.

Discussion
==========

SRC, which is a member of the SRC tyrosine kinases family, is a proto-oncogene encoding for the tyrosine kinase being localized in the cell membrane as well as in the cytosol. SRC plays a crucial role in the regulation of cell differentiation, adhesion, migration, proliferation, invasion and angiogenesis by interacting with different receptor tyrosine kinases like epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), epidermal growth factor receptor 3 (HER-3) or vascular endothelial growth factor receptor (VEGFR) and being part in different cellular pathways (e.g. PI3K/Akt/Ras/Raf/MAPK).[@B24],[@B25],[@B27],[@B39] SRC inhibitors (e.g. dasatinib, bosutinib and saracatinib), which have entered the clinics, are currently being tested in phase-II-/III-trials as the tyrosine kinase represents a potential target of future oncological therapy. This analysis is the largest study so far evaluating SRC expression in pretherapeutic biopsies and corresponding resection specimens from patients with rectal cancer. In this analysis, we could not find any correlation between SRC expression and therapeutic response in terms of early surrogate parameters to preoperative CRT (TRG, tumor downsizing/ downstaging).

Regarding the prognostic potential of SRC, we could demonstrate that high SRC expression in rectal cancer was associated with a better long-term outcome. However, there is only limited data disposable considering the role of SRC in CRC.

Other studies examined the role of SRC in other cancers (e.g. breast cancer, cancer of the uterus, liver cancer).[@B40]-[@B42] Considering these different tumor entities, high SRC expression was associated with a positive nodal status as well as with a reduced DFS and overall survival (OS). Theocharis *et al.*showed that SRC expression correlated with prolonged DFS and OS in patients with squamous tongue cancer.[@B43]

It is arguable whether monitoring of SRC could be a future diagnostic tool and whether SRC inhibition might improve clinical outcome under preoperative CRT, as the tyrosine kinase might represent a future therapeutic target.

Besides that, examining the role of SRC in trastuzumab resistance in HER2-positive patients could be another step towards individualized therapy strategies. Many recent studies demonstrated that SRC expression is involved in trastuzumab resistance in patients with HER-2 positive breast cancer.[@B44]-[@B46] There is some promising data available postulating that targeting of SRC might improve the response to trastuzumab treatment in HER2-expressing cancer patients.

The TRG represents an early surrogate parameter.[@B6],[@B47], besides the pathological determined lymph node status (ypN) being the most important prognostic factor in rectal cancer patients.[@B48] It is debatable whether a high SRC expression in combination with an intermediate TRG regression (TRG 2-3) and a negative nodal status in rectal cancer patients could be associated with a better prognosis and would not need any further therapeutic steps, while patients with a positive nodal status (ypN+) and a low SRC expression would postoperatively require intensified therapy. In the future the role of SRC as therapeutic target in particular in HER-2 overexpressing tumors should be further investigated based on the assumption that SRC expressing cancer cells are hyperproliferative.

An analysis by Perez *et al.* could demonstrate the importance of SRC and its inhibitors stating that the inhibition of SRC sensitized liver metastatic colorectal carcinoma to oxaliplatin.[@B49] Interestingly, in our study population, patients with a high pretreatment SRC expression seemed to have benefited from a treatment schedule including oxaliplatin. Furthermore, Kopetz *et al.* showed that higher levels of phosphorylated SRC (pSRC) in patients with hepatic metastasized colorectal cancer were significantly associated with shorter relapse-free survival.[@B50] In contrast to our analysis, metastatic tissue and phosphorylated SRC were analyzed. It is therefore possible that a different activation state of SRC has a different impact on clinicopathological parameters and patient survival.[@B51] Earlier studies also revealed a significantly higher SRC activity in tissue of hepatic metastases compared to the corresponding primary tumor *in vivo*which might explain different findings.[@B52]

Modifications like phosphorylation or dephosphorylation can affect the kinase activity of SRC. While we examined not specifically the significance of phosphorylated versus unphosphorylated SRC expression in tissue, further examinations with this distinction would be desirable in order to compare different SRC kinase activity states with prognostic parameters.

In order to implement pretherapeutic SRC expression level assessment into clinical practice, prospective validations of this study with larger patient cohorts would be essential. Detecting further markers for the patient´s individual risk for cancer relapse and stratification of patients for the postoperative treatment would be desirable. The prospectively randomized clinical trial stratification of patients for the preoperative CRT regimen according to SRC expression would be the next step towards a risk-adapted, more individualized multimodal therapy.

In conclusion, this study evaluated the predictive and prognostic role of SRC in locally advanced rectal cancer (UICC stages II and III) treated with multimodal preoperative 5-FU-based CRT. The analyses show a favorable prognosis in patients with high SRC expression in pretherapeutic tissue as well as in resection specimens. High SRC expression in rectal cancer seems to be associated with a better long-term outcome. This finding could help in the future to stratify patients according to pretreatment SRC expression for a recurrence risk adapted preoperative treatment and should be validated and further analyzed within clinical trials. Furthermore its potential as a new therapeutic target in CRC should be evaluated. So far, SRC inhibition with e.g. saracatinib did not show a satisfying treatment success as a single agent in previously treated metastatic CRC patients[@B53], however is currently being tested in multiple clinical trials for different entities of advanced cancer[@B54], [@B55] and might be a valuable addition to combination therapies for rectal cancer patients in the future.

Due to the limited data of SRC expression in rectal cancer tissue, our findings should be further validated and evaluated in large other cohorts of patients. Furthermore, our analysis is of retrospective nature and prospective studies would be desirable.
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![**Study design.** This figure shows the treatment of patients and time points of tissue collection for analysis of SRC expression. CEA, carcinoembryonic antigen; CT, contrast-enhanced computer tomography; EUS indicates endorectal ultrasound; MRI, magnetic resonance imaging; CSS, Cancer specific survival; DFS, Disease free survival; ox, oxaliplatin.](jcav08p1229g001){#F1}

###### 

**Images of immunhistochemical staining in resection specimens of rectal cancer: A**SRC cytosolic staining intensity 0 in 40x magnification, **B** SRC cytosolic staining intensity in 40x magnification, **C**SRC cytosolic staining intensity in 40x magnification, **D**SRC cytosolic staining intensity III in 40x magnificationon.
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![**A) Correlation between SRC expression in pretherapeutic biopsies and the nodal status in cytosolic staining:** high SRC expression is associated with fewer lymph node metastases (p=0.005). **B) Correlation between pretherapeutic SRC expression under preoperative CRT with 5-FU/oxaliplatin and the nodal status:** On the basis of the ROC curve (receiver operating characteristic curve) there is a high specificity and sensitivity regarding the correlation between the pretherapeutic SRC expression for patients receiving preoperative CRT with 5-FU and oxaliplatin and the nodal status. The AUC (area under curve) is 81.2%, representing the quality of the test.](jcav08p1229g004){#F3}

![**Correlation between cytosolic SRC expression in resection specimens and the occurrence of distant metastases:** high SRC expression is associated with fewer distant metastases (p=0.048).](jcav08p1229g005){#F4}

###### 

Clinicopathologic parameters and Histopathologic Characteristics of Examined Patients (n=186)

  Parameters/ Characteristics                        Primary surgery (n=27)   Preoperative CRT with 5-FU (n=103)   Preoperative CRT with 5-FU + oxaliplatin (n=56)   p-value †
  -------------------------------------------------- ------------------------ ------------------------------------ ------------------------------------------------- -----------
  **Age**\[years\]                                                                                                                                                   0.61\#
  Mean                                               64.9                     63.6                                 62.4                                              
  Range                                              44-81                    35-83                                37-82                                             
  **Sex**                                                                                                                                                            0.56
  Male                                               17 (63%)                 75 (73%)                             38 (68%)                                          
  Female                                             10 (37%)                 28 (27%)                             18 (32%)                                          
  **Tumor localization**(above anocutaneous verge)                                                                 0.08                                              
  0-6 cm                                             9 (33%)                  45 (44%)                             23 (41%)                                          
  \>6-12 cm                                          12 (44%)                 51 (50%)                             31 (55%)                                          
  \>12-16 cm                                         6 (22%)                  6 (6%)                               2 (4%)                                            
  **cT stage**                                                                                                                                                       0.01
  T1                                                 1 (4%)                   \-                                   \-                                                
  T2                                                 5 (19%)                  5 (5%)                               1 (2%)                                            
  T3                                                 19 (70%)                 92 (89%)                             54 (96%)                                          
  T4                                                 2 (7%)                   6 (6%)                               1 (2%)                                            
  **cN stage**                                                                                                                                                       0.29
  positive (cN+)                                     17 (63%)                 72 (70%)                             41 (73%)                                          
  negative (cN-)                                     10 (37%)                 30 (29%)                             15 (27%)                                          
  unknown                                            \-                       1 (1%)                               \-                                                
  **cUICC stage**                                                                                                                                                    0.02
  I                                                  3 (11%)                  \-                                   \-                                                
  II                                                 7 (26%)                  31 (30%)                             12 (21%)                                          
  III                                                15 (56%)                 70 (68%)                             41 (73%)                                          
  IV                                                 2 (7%)                   2 (2%)                               3 (5%)                                            
  **Surgical procedure**                                                                                                                                             0.27
  Low anterior resection                             20 (71%)                 61 (59%)                             43 (77%)                                          
  Abdominoperineal resection                         6 (21%)                  38 (37%)                             12 (21%)                                          
  Hartmann procedure                                 2 (7%)                   4 (4%)                               1 (2%)                                            
  **Resection margin**                                                                                                                                               0.03
  R0                                                 25 (93%)                 102 (99%)                            56 (100%)                                         
  R1                                                 2 (7%)                   1 (1%)                               \-                                                
  **TRG**                                                                                                                                                            0.68
  0                                                  \-                       \-                                   \-                                                
  1                                                  \-                       14 (14%)                             5 (9%)                                            
  2                                                  \-                       30 (29%)                             14 (25%)                                          
  3                                                  \-                       51 (49%)                             33 (59%)                                          
  4                                                  \-                       8 (8%)                               4 (7%)                                            
  **(y)pT stage**                                                                                                                                                    0.47
  0                                                  1 (4%)                   8 (8%)                               4 (7%)                                            
  1                                                  2 (7%)                   5 (5%)                               9 (16%)                                           
  2                                                  9 (33%)                  25 (24%)                             12 (21%)                                          
  3                                                  13 (48%)                 59 (57%)                             28 (50%)                                          
  4                                                  2 (7%)                   6 (6%)                               3 (6%)                                            
  **(y)pN stage**                                                                                                                                                    0.1
  0                                                  16 (59%)                 64 (62%)                             43 (77%)                                          
  1                                                  5 (19%)                  23 (22%)                             11 (20%)                                          
  2                                                  6 (22%)                  16 (16%)                             2 (3%)                                            
  **(y)pUICC stage**                                                                                                                                                 0.48
  0                                                  1 (4%)                   7 (7%)                               4 (7%)                                            
  I                                                  8 (30%)                  21 (20%)                             20 (36%)                                          
  II                                                 7 (26%)                  33 (32%)                             16 (28%)                                          
  III                                                9 (33%)                  35 (34%)                             11 (20%)                                          
  IV                                                 2 (7%)                   7 (7%)                               5 (9%)                                            
  **Cancer recurrence**                                                                                                                                              0.83
  None                                               17 (63%)                 69 (67%)                             39 (70%)                                          
  Local                                              3 (11%)                  1 (1%)                               1 (1%)                                            
  Distant                                            7 (26%)                  33 (32%)                             16 (29%)                                          
  **Distant metastases**                                                                                                                                             
  Hepatic                                            1 (14%)                  9 (27%)                              6 (38%)                                           
  Pulmonary                                          4 (57%)                  12 (36%)                             2 (12%)                                           0.25
  Peritoneal / other                                 2 (29%)                  12(36%)                              8 (50%)                                           
  **Follow-up time**                                                                                                                                                 
  Median                                             110,0                    60,0                                 48,5                                              
  Range                                              21-163                   1-163                                3-110                                             
  Mean                                               96,3                     66,4                                 49,0                                              
  Standard deviation                                 40,7                     37,1                                 24,1                                              
  **Cancer related death**                           7 (26)                   10 (18)                              19 (18)                                           

†P-values from χ[@B2] test; \# P-values from Kruskal-Wallis Test
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